MedTrace Logo

Cough Reduction in IPF With Nalbuphine ER

NCT05964335 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 165

Last updated 2025-06-27

No results posted yet for this study

Summary

The main purpose of the study is to evaluate the effect of NAL ER on 24-hour cough frequency using objective digital cough monitoring and to assess safety and tolerability of NAL ER.

Conditions

Interventions

DRUG

NAL ER

Oral tablets

DRUG

Placebo

Oral tablets

DRUG

NAL ER

Oral Tablets

DRUG

NAL ER

Oral tablets

Sponsors & Collaborators

  • Trevi Therapeutics

    lead INDUSTRY

Principal Investigators

  • Chief Development Officer · Trevi Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-06
Primary Completion
2025-04-24
Completion
2025-04-24
FDA Drug
Yes

Countries

  • Australia
  • Canada
  • Chile
  • Germany
  • Italy
  • Netherlands
  • Poland
  • Spain
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05964335 on ClinicalTrials.gov